The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJOncoAlert Journal Club | FRONT-BRAF: 1L IO +/- chemo vs BRAF + MEKi in BRAFV600E-m mNSCLC
In this latest episode of the VJOncoAlert Journal Club, Biagio Ricciuti, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the FRONT-BRAF trial, where first-line (1L) immune checkpoint inhibitors with or without chemotherapy were associated with improved overall survival compared with BRAF and MEK inhibitors in participants with metastatic BRAFV600E-mutated non-small cell lung cancer (mNSCLC), particularly among specific subpopulations.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
